We are live on ! Find out more
PVI

Pura Vida Investments Portfolio holdings

AUM $14.9M
1-Year Est. Return 38.76%
This Fund
S&P 500
This Quarter Est. Return
+26.22%
1 Year Est. Return
+38.76%
3 Year Est. Return
+26.8%
5 Year Est. Return
+25.03%
10 Year Est. Return
+1,723.84%
AUM
$475M
AUM Growth
+$226M
Cap. Flow
+$193M
Cap. Flow %
40.57%
Top 10 Hldgs %
41.72%
Holding
154
New
62
Increased
25
Reduced
13
Closed
48

Top Buys

Rank Stock Value
1
BSX icon
Boston Scientific
BSX
+$7.96M
2
AMGN icon
Amgen
AMGN
+$5.99M
3
AZTA icon
Azenta
AZTA
+$5.35M
4
ESTA icon
Establishment Labs
ESTA
+$5.33M
5
CNC icon
Centene
CNC
+$5.26M

Top Sells

Rank Stock Value
1
SIEN
Sientra, Inc.
SIEN
+$3.59M
2
HOLX
Hologic
HOLX
+$3.48M
3
ATHN
Athenahealth, Inc.
ATHN
+$3.34M
4
AGN
Allergan plc
AGN
+$3.33M
5
VRTX icon
Vertex Pharmaceuticals
VRTX
+$2.55M

Sector Composition

Rank Sector Weight
1 Healthcare 35.48%
2 Industrials 0.59%
3 Technology 0.39%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OFIX icon
26
Orthofix Medical
OFIX
$428M
$5.26M 1.11%
+91,058
New +$5.1M
ZBH icon
27
Zimmer Biomet
ZBH
$18.6B
$5.26M 1.11%
+41,200
New +$4.9M
WMGI
28
DELISTED
Wright Medical Group Inc
WMGI
$5.14M 1.08%
177,178
+102,178
+136% +$2.75M
ESTA icon
29
Establishment Labs
ESTA
$2.21B
$5.01M 1.05%
+207,882
New +$5.33M
XBI icon
30
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.4B
$4.79M 1.01%
50,000
-50,000
-50% -$4.85M
SMH icon
31
PUT
VanEck Semiconductor ETF
SMH
$70.2B
$4.79M 1.01%
+90,000
New +$4.78M
SYNH
32
DELISTED
Syneos Health, Inc. Class A Common Stock
SYNH
$4.7M 0.99%
91,120
+21,120
+30% +$1.03M
BAX icon
33
Baxter International
BAX
$14.3B
$4.63M 0.97%
60,000
+20,000
+50% +$1.48M
AERI
34
CALL
DELISTED
Aerie Pharmaceuticals
AERI
$4.62M 0.97%
+75,000
New +$4.82M
REGN icon
35
CALL
Regeneron Pharmaceuticals
REGN
$83.3B
$4.04M 0.85%
+10,000
New +$3.81M
AZN icon
36
CALL
AstraZeneca
AZN
$247B
$3.96M 0.83%
+50,000
New +$3.78M
EHC icon
37
PUT
Encompass Health
EHC
$12.4B
$3.9M 0.82%
+62,850
New +$3.82M
KIDS icon
38
OrthoPediatrics
KIDS
$630M
$3.69M 0.78%
100,834
+26,449
+36% +$810K
AMRN
39
Amarin Corp
AMRN
$300M
$3.66M 0.77%
+11,250
New +$850K
ITCI
40
PUT
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$3.65M 0.77%
+168,100
New +$3.51M
OMCL icon
41
PUT
Omnicell
OMCL
$1.68B
$3.6M 0.76%
+50,000
New +$3.15M
ADMA icon
42
ADMA Biologics
ADMA
$2.22B
$3.55M 0.75%
571,317
+246,317
+76% +$1.42M
ELAN icon
43
Elanco Animal Health
ELAN
$11.4B
$3.49M 0.73%
+100,000
New +$3.52M
NVRO
44
PUT
DELISTED
NEVRO CORP.
NVRO
$3.42M 0.72%
60,000
– –
NVTR
45
CALL
DELISTED
Nuvectra Corporation Common Stock
NVTR
$3.3M 0.69%
+150,000
New +$2.89M
GMED icon
46
Globus Medical
GMED
$11.5B
$3.26M 0.69%
57,500
-10,000
-15% -$526K
AMRN
47
PUT
Amarin Corp
AMRN
$300M
$3.25M 0.68%
+10,000
New +$755K
TNDM icon
48
Tandem Diabetes Care
TNDM
$1.61B
$3.25M 0.68%
+75,933
New +$2.65M
TMO icon
49
PUT
Thermo Fisher Scientific
TMO
$222B
$3.05M 0.64%
+12,500
New +$2.88M
VAR
50
PUT
DELISTED
Varian Medical Systems, Inc.
VAR
$2.8M 0.59%
+25,000
New +$2.83M
1
2
3 4 5

Similar funds

BCA
Boundary Creek Advisors New York $15.3M AUM 0.41% 1-Year Est. Return
RC
Raine Capital New York $14.1M AUM 33.16% 1-Year Est. Return
DOFI
DCVC Opportunity Fund II Palo Alto, California $13.9M AUM 8.04% 1-Year Est. Return
SCI
SkyBridge Capital II New York $13.1M AUM 3.36% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
GBCP
Glade Brook Capital Partners Greenwich, Connecticut $12.8M AUM
SCTC
Samsung C&T Corporation Seoul, South Korea $17.2M AUM 23.45% 1-Year Est. Return
M
MetLife New York $12.3M AUM 29% 1-Year Est. Return

Pura Vida Investments's Q3 2018 Portfolio in Review

As of Q3 2018, Pura Vida Investments held 154 positions worth $475M, up 91% from $250M the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Pura Vida Investments deployed $193M of net new capital in Q3 2018, opening 62 new positions and adding to 25 existing holdings. Its largest new stake was Amgen: 30,373 shares worth $6.3M.

By sector, the portfolio is most concentrated in Healthcare at 35% of assets, down from 37% a quarter earlier, followed by Industrials and Technology.

On the sell side, the largest reduction was Madrigal Pharmaceuticals, an estimated $2.36M trimmed.

  • Pura Vida Investments's largest Q3 2018 buy was Amgen: 30,373 shares worth $6.3M.
  • Pura Vida Investments added most to Boston Scientific in Q3 2018, an estimated $7.96M increase.
  • Pura Vida Investments's biggest Q3 2018 reduction was Madrigal Pharmaceuticals, cutting an estimated $2.36M.
  • Pura Vida Investments fully exited Sientra, Inc. in Q3 2018, selling an estimated $3.59M.
  • Pura Vida Investments's ten largest holdings make up 42% of its $475M portfolio in Q3 2018.
  • Pura Vida Investments opened 62 new positions and closed 48 in Q3 2018.
  • Pura Vida Investments's portfolio value rose 91% quarter-over-quarter to $475M.

Based on Pura Vida Investments's 13F filing for Q3 2018, filed 14 Nov 2018.